Traders place overwhelming odds against a new COVID variant of concern emerging before 2027 because ongoing genomic surveillance of SARS-CoV-2 reveals no strains combining the elevated transmissibility, disease severity, or immune escape needed for WHO reclassification. After Omicron lineages stabilized, later subvariants have shown only incremental changes that health authorities continue tracking at lower alert levels. Widespread population immunity from prior infections and vaccinations has further slowed the pace of impactful evolution, reinforcing the market's near-certain consensus reflected in current pricing. An unexpected mutation cluster capable of rapid dominance could still shift assessments if monitoring data suddenly highlights concerning traits.